Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.68 |
| ▸ | ACE | P12821 | 10/20 | 0.68 |
| ▸ | CPA1 | P15085 | 2/20 | 0.68 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.67 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616915 | 1.00 | MME (0.68) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL24821176 | 0.89 | MME (0.67) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL4572624 | 0.89 | MME (0.67) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL10425350 | 0.89 | MME (0.67) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL8522309 | 0.88 | ACE (0.76) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL10424762 | 0.88 | MME (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL2493049 | 0.88 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL2545591 | 0.88 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL16481670 | 0.88 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL4073351 | 0.88 | ACE (0.65) | MMEACECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-6916800-B2 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | PFIZER INC (US) | 2005-07-12 | — | — | US | disclosed |
| US-6858598-B1 | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | G. D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | MME 4324/4885ACE 2448/4885CPA1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.